M. Florentin, M. S. Elisaf, D. P. Mikhailidis and E. N. Liberopoulos Pages 3446 - 3462 ( 17 )
Metabolic syndrome (MetS) is a cluster of risk factors, each one individually associated with increased cardiovascular disease risk. Treatment of all components of MetS is expected to result in reduced risk. Treatment of MetS mainly includes lifestyle changes. In addition, drug therapy may be considered, especially combinations of different drugs, in order to tackle all the features of MetS. We review the therapeutic strategies currently used for obesity and dyslipidemia treatment in patients with MetS, with a focus on drug combinations.
Bile acid sequestrants,ezetimibe,fibrates,metabolic syndrome,niacin,orlistat,rimonabant,statins
, , , Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital,Royal Free and University College School of Medicine, Pond Street, London NW3 2QG, UK.